# Ovid Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ovid-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.ovidrx.com
- Total disclosed funding: $75M
- Latest round: Series B (Aug 11, 2015)
- Investors on record: 9

## About

Ovid Therapeutics Inc. is a biotechnology company focused on developing innovative small molecule therapies for neurological disorders, particularly epilepsy and brain conditions that significantly impact patients' lives.Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, US. The company specializes in creating therapies for neurological diseases, specifically targeting epilepsies. The company has successfully raised USD 50.00 mn in a Private Placement/Follow on funding round in 2020, which contributed to their overall funding total of USD 50.00 mn. The CEO of Ovid is Jeremy Levin.Ovid Therapeutics specializes in developing targeted small molecule therapies aimed at addressing neurological diseases, particularly epilepsies and brain conditions. The company’s core product offerings center around innovative compounds designed to reduce seizure frequency while enhancing safety and tolerability for patients. These therapies operate on unique or potentially best-in-class mechanisms of action, reflecting Ovid's commitment to pioneering effective treatments that could significantly alter disease trajectories. The end-users include children and adults affected by epilepsy and cerebral cavernous malformations, with the company actively engaging with these communities to inform its therapeutic development. Ovid's products are marketed primarily in North America and Europe, targeting healthcare providers, specialists, and hospitals that serve patients with these neurological disorders.Ovid Therapeutics generates revenue through direct partnerships and collaborations focused on the development and commercialization of its pharmaceutical products. The transaction structure typically involves agreements with healthcare institutions and specialty pharmacies, which facilitate the distribution of their therapies to patients and healthcare providers. The company's revenue for the most recent year (2024) is USD 566,000, with an EBITDA of USD -61,885,000.Ovid Therapeutics is focused on expanding its product pipeline and developing new therapies aimed at treating neurological conditions, with prospective launches planned in the coming years. The company is looking to enter new markets within Europe and Asia by 2025. Recent funding will support these initiatives, enhancing their research and development capabilities to advance their products towards commercialization.

## Funding rounds

- Series B, Aug 11, 2015, $75M — Tekla Capital Management, Fidelity Investments, DoubleLine LLC, Sanofi Ventures, Sphera Fund Management, Jennison Associates, Redmile Group, Cormorant Asset Management, Cowen Investment Management

## Investors

- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- DoubleLine LLC — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Sphera Fund Management — Series B
- Jennison Associates — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Cowen Investment Management — Series B